Overcoming the bottlenecks in financing young biotech companies

Inhaltsverzeichnis (Table of Contents)

• Introduction
• Definitions, Characteristics and Classifications
  • Biotech
    • Business Segments
    • Business Categories
    • Business Models
    • Business Framework
  • Young Companies
    • Company Formation
    • Growth and Challenges
    • Specific Characteristics of Young Biotech Companies
  • Financing
    • Models of Entrepreneurial Finance
    • Business Angels / Family Offices
    • Venture Capital
    • Subsidies
    • Other Financing Instruments and Sources
  • Munich Cluster
    • BioRegio Contest
    • Current State of the BioM Region
• The Challenge of Financing Young Biotech Companies
  • Risks and Resultant Financial Implications
  • Biotech Financing Cycles
  • The Eminence of a Current Bottleneck
• Experiences from the Munich Cluster – Interview Analysis
  • Scope, Sample and Sequence of Interviews
  • Financial Sector Activity
    • Specifications of the Bottlenecks
    • Drivers of the Bottlenecks
    • Starting-Points to Improve
  • Financial Cluster Activity
  • Financial Company Activity
    • Financing Strategy
    • Financing Status Quo
    • Financing Lessons Learned
  • Financial Investor Activity
    • Investment Peripherals
    • Investment Criteria
  • Interview Results and Evaluation
• Tackling the Bottlenecks
  • Elements of a Successful Financial Strategy
  • Endogenous Strategies - Avenues for Biotech Companies
    • Big Money Model I: Biotech Venture Capital
    • Big Money Model II: Co-operations and Alliances
    • Low Budget Model
  • Exogenous Strategies - Avenues for the Framework
    • Cluster and Regional Strategies
    • National Strategies
    • General Societal Strategies
  • A Comprehensive Biotech Financing Cycle
• Summary and Outlook

Zielsetzung und Themenschwerpunkte (Objectives and Key Themes)

This thesis aims to address the research question of how to overcome specific bottlenecks in financing young biotech companies. The main objective is to identify the root causes of these bottlenecks and develop strategies to effectively address them.

• The unique challenges of financing young biotech companies
• Specific bottlenecks in financing young biotech companies
• The role of cluster structures in addressing financial challenges
• Strategies for overcoming bottlenecks at the company, regional, national, and societal levels
• The impact of personalized medicine on future financing landscapes

Zusammenfassung der Kapitel (Chapter Summaries)

Chapter 2 provides definitions and descriptions of key concepts such as biotechnology, young companies, and financing. This chapter establishes the theoretical framework for the research question and outlines the specific characteristics and challenges associated with each pillar.

Chapter 3 combines these individual pillars and elaborates on the challenge of financing young biotech companies. The chapter examines the inherent risks of the industry, its financial implications, historical financing cycles, and the prominence of a current bottleneck.

Chapter 4 presents the results of qualitative interviews conducted in the Munich biotech cluster. This chapter investigates the perspectives of biotech executives, venture capitalists, and external industry experts, exploring their experiences with financial bottlenecks and suggesting possible solutions.

Schlüsselwörter (Keywords)

The primary keywords and focus topics of this work include financing, young biotech companies, financial bottlenecks, venture capital, cluster structures, and personalized medicine. The study explores the challenges and opportunities surrounding the financing of innovative, early-stage biotechnology firms, highlighting the need for strategic approaches to address the financial gap.